American millionaire Jonathan Lehrer denied bail after being charged with killing Canadian couple
American millionaire Jonathan Lehrer, one of two men charged in the killings of a Canadian couple in Dominica, has been denied bail.
The first new Alzheimer's treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works.
Several major medical centers remain undecided on whether to use Biogen's Aduhelm, which is recommended for early stages of the disease. Big names like the Cleveland Clinic and Mass General Brigham in Boston say they'll pass on it for now.
One neurology practice has even banned the company's sales reps from its offices, citing concerns about the drug and its price, which can climb past US$50,000 annually.
Many doctors say they need to learn more about how Aduhelm works and what will be covered before they decide whether to offer it. That might take several months to sort out. Even then, questions may linger.
"The drug won't be for everybody, even with access," said Salim Syed, an analyst who covers Biogen for Mizuho Securities USA.
Syed estimates that only around one-tenth of the people diagnosed with early-stage Alzheimer's may wind up taking Aduhelm chronically, especially if regulators approve similar treatments from Biogen's competitors.
Biogen, which reports third-quarter financial results Wednesday, is not saying how many people have received the drug since it was approved on June 7.
A company executive said last month that Biogen was aware of about 50 sites infusing Aduhelm, far fewer than the 900 the company had said it expected to be ready shortly after regulators approved the drug.
Aduhelm is the first in a line of new drugs that promise to do what no other Alzheimer's treatment has managed: slow the progress of the fatal brain-destroying disease instead of just managing its symptoms.
"It's like a breath of fresh air," said Dr. Stephen Salloway, a Rhode Island neurologist and Biogen consultant who is prescribing the drug. People with Alzheimer's "know what's coming, and they want to do whatever they can to stay in the milder stage."
The U.S. Food and Drug Administration approved Aduhelm despite objections from its own independent advisers, several of whom resigned. The agency later said the drug was appropriate for patients with mild symptoms or early-stage Alzheimer's.
Aduhelm clears brain plaque thought to play a role in Alzheimer's disease, and regulators made the call based on study results showing the drug seemed likely to benefit patients.
Biogen, which developed Aduhelm with Japan's Eisai Co., had halted two studies on the drug due to disappointing results. It later said further analysis showed the treatment was effective at higher doses.
The FDA is requiring Biogen to conduct a follow-up study.
The research Biogen submitted so far doesn't give doctors as much insight as they would normally have into a drug, said Dr. Brendan Kelley, a neurologist at UT Southwestern Medical Center in Dallas. Its experts are still reviewing Aduhelm.
"Biogen went to the FDA with preliminary data, so it makes it really challenging to know how to navigate," he said. More complete research would give doctors a better idea for how the drug will work in a broader patient population, Kelley said.
Cost is another concern.
Biogen's pricing for Aduhelm is "irresponsible and unconscionable," according to signs posted on office doors for The Neurology Center, a Washington, D.C.-area practice. The signs also refer to Aduhelm as a medication "of dubious effectiveness" and tell Biogen sales reps they are no longer welcomed in the center's offices.
"As physicians we feel compelled to speak out and protest BIOGEN's actions," one of the signs reads.
Neurology Center CEO Wendy Van Fossen said the signs went up in July, but she declined to elaborate on why they were posted.
A Biogen spokeswoman said in an email that it was disappointing that some centers are denying access to the drug.
As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. She said regulators reviewed data from more than 3,000 patients, counting two late-stage studies and earlier research.
Doctors also are worried about whether patients taking Aduhelm will be able to get the regular brain scans needed to monitor their progress on the drug.
Issues with care access weren't explored in the clinical research, which also involved patients who were generally younger and healthier than those in the broader population, noted Dr. Zaldy Tan, director of the Cedars-Sinai memory and aging program.
The Los Angeles health system is still evaluating Aduhelm. Its committee of experts is considering things like which doctors will prescribe the drug and how to ensure patients are monitored for problems like dizziness or headaches develop. Bleeding in the brain is another potential side effect.
"Safety and access are real issues that need to be prioritized," Tan said.
Aduhelm also requires a deeper level of coordination among doctors than other Alzheimer's treatments, noted Radhakrishnan.
Prescribing doctors have to work with neurologists, radiologists and nurse practitioners to diagnose patients, confirm the presence of plaque in the brain, get them started on the treatment and then monitor them.
"All of this is work in progress," Radhakrishnan said.
Uncertainty about insurance coverage is another holdup.
Some insurers have decided not to cover the drug. Others, including the major Medicare Advantage insurer Humana, haven't made a decision yet but are reviewing claims case by case in the meantime.
The federal Medicare program is expected to make a national coverage determination by next spring that will lay out how it handles the drug.
Biogen executives said recently they think most sites that will offer the drug are waiting for clarity on reimbursement, including that Medicare decision.
Medicare's determination looms large for the Cedars-Sinai experts. Tan said they know they should reach a decision before the Medicare decision prompts more patient inquiries.
He said doctors also realize they aren't just evaluating Aduhelm: They're also thinking about how to handle similar treatments that could get FDA approval.
"We want to make sure we get it right," Tan said.
------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
American millionaire Jonathan Lehrer, one of two men charged in the killings of a Canadian couple in Dominica, has been denied bail.
The judge presiding over the trial of a man accused of fatally running over a Toronto police officer is telling jurors the possible verdicts they may reach based on the evidence in the case.
Nearly half of China's major cities are suffering 'moderate to severe' levels of subsidence, putting millions at risk of flooding especially as sea levels rise.
Cabinet minister Dominic LeBlanc says he plans to run in the next election as a candidate under Prime Minister Justin Trudeau's leadership, amid questions about his rumoured interest in succeeding his longtime friend for the top job.
A male columnist has apologized for a cringeworthy moment during former University of Iowa superstar and college basketball's highest scorer Caitlin Clark's first news conference as an Indiana Fever player.
Health Canada will change its longstanding policy restricting gay and bisexual men from donating to sperm banks in Canada, CTV News has learned. The federal health agency has adopted a revised directive removing the ban on gay, bisexual and other men who have sex with men, effective May 8.
Prince Harry, the son of King Charles III and fifth in line to the British throne, has formally confirmed he is now a U.S. resident.
The United States has vetoed a widely backed UN resolution that would have paved the way for full United Nations membership for the state of Palestine.
Sophie Kinsella, the best-selling author behind the 'Shopaholic' book series, has revealed that she is receiving treatment for brain cancer.
Kevin the cat has been reunited with his family after enduring a harrowing three-day ordeal while lost at Toronto Pearson International Airport earlier this week.
Molly Knight, a grade four student in Nova Scotia, noticed her school library did not have many books on female athletes, so she started her own book drive in hopes of changing that.
Almost 7,000 bars of pure gold were stolen from Pearson International Airport exactly one year ago during an elaborate heist, but so far only a tiny fraction of that stolen loot has been found.
When Les Robertson was walking home from the gym in North Vancouver's Lower Lonsdale neighbourhood three weeks ago, he did a double take. Standing near a burrow it had dug in a vacant lot near East 1st Street and St. Georges Avenue was a yellow-bellied marmot.
A moulting seal who was relocated after drawing daily crowds of onlookers in Greater Victoria has made a surprise return, after what officials described as an 'astonishing' six-day journey.
Just steps from Parliament Hill is a barber shop that for the last 100 years has catered to everyone from prime ministers to tourists.
A high score on a Foo Fighters pinball machine has Edmonton player Dave Formenti on a high.
A compound used to treat sour gas that's been linked to fertility issues in cattle has been found throughout groundwater in the Prairies, according to a new study.
While many people choose to keep their medical appointments private, four longtime friends decided to undergo vasectomies as a group in B.C.'s Lower Mainland.